Concord Biotech Limited (CONCORDBIO) — Capital Reinvestment Ratio
Concord Biotech Limited (CONCORDBIO) has a Capital Reinvestment Ratio of 0.45x as of March 2025, meaning it reinvests 0% of its operating cash flow (Rs2.47 Billion) in capital expenditures (Rs1.11 Billion). Check CONCORDBIO tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Concord Biotech Limited Capital Reinvestment Ratio (2020–2025)
This chart tracks Concord Biotech Limited's Capital Reinvestment Ratio across 6 annual periods. For the full cash flow conversion analysis, see Concord Biotech Limited cash conversion from operations.
Annual Capital Reinvestment Ratio for Concord Biotech Limited (2020–2025)
Year-by-year Capital Reinvestment Ratio for Concord Biotech Limited from 2020 to 2025. See Concord Biotech Limited free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (INR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.45x | Rs2.47 Billion | Rs1.11 Billion | ▲ +39.2% |
| 2024 | 0.32x | Rs2.65 Billion | Rs856.88 Million | ▼ -45.3% |
| 2023 | 0.59x | Rs2.46 Billion | Rs1.45 Billion | ▼ -21.3% |
| 2022 | 0.75x | Rs2.07 Billion | Rs1.56 Billion | ▼ -38.8% |
| 2021 | 1.22x | Rs1.67 Billion | Rs2.04 Billion | ▲ +21.9% |
| 2020 | 1.00x | Rs1.55 Billion | Rs1.55 Billion | — |